Background: Genetic, biologic and clinical data suggest that Parkinson's disease (PD) is an umbrella for multiple disorders with clinical and pathological overlap, yet with different underlying mechanisms. To better understand these and to move towards neuroprotective treatment, we have established the Quebec Parkinson Network (QPN), an open-access patient registry, and data and bio-samples repository.
Objective: To present the QPN and to perform preliminary analysis of the QPN data.
Methods: A total of 1,070 consecutively recruited PD patients were included in the analysis. Demographic and clinical data were analyzed, including comparisons between males and females, PD patients with and without RBD, and stratified analyses comparing early and late-onset PD and different age groups.
Results: QPN patients exhibit a male:female ratio of 1.8:1, an average age-at-onset of 58.6 years, an age-at-diagnosis of 60.4 years, and average disease duration of 8.9 years. REM-sleep behavior disorder (RBD) was more common among men, and RBD was associated with other motor and non-motor symptoms including dyskinesia, fluctuations, postural hypotension and hallucinations. Older patients had significantly higher rates of constipation and cognitive impairment, and longer disease duration was associated with higher rates of dyskinesia, fluctuations, freezing of gait, falls, hallucinations and cognitive impairment. Since QPN's creation, over 60 studies and 30 publications have included patients and data from the QPN.
Conclusions: The QPN cohort displays typical PD demographics and clinical features. These data are open-access upon application (http://rpq-qpn.ca/en/), and will soon include genetic, imaging and bio-samples. We encourage clinicians and researchers to perform studies using these resources.
Keywords: Parkinson disease; Quebec Parkinson Network; biobank; registry.
Conflict of interest statement
ZGO reports consultation fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Denali, Prevail Therapeutics, Inception Sciences (Ventus), all outside the submitted work. AD received research grants from Flamel Ireland Limited, Pfizer, Canopy Growth, Biron as well as honoraria from speaking engagements from UCB and Biogen. None of the financial disclosures is relevant to the submitted work. RBP reports personal fees from Takeda, Roche/Prothena, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, Jazz Pharmaceuticals, Abbvie, Jannsen, and Otsuko, all outside the submitted work.
All other authors have no conflict of interests to report.
Frequency of REM sleep behavior disorders in patients with Parkinson's disease.Vojnosanit Pregl. 2015 May;72(5):442-6. doi: 10.2298/vsp130501006j. Vojnosanit Pregl. 2015. PMID: 26165053
REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson's disease.Parkinsonism Relat Disord. 2014 Oct;20(10):1081-4. doi: 10.1016/j.parkreldis.2014.03.022. Epub 2014 Apr 1. Parkinsonism Relat Disord. 2014. PMID: 25085747
Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection.J Parkinsons Dis. 2016 Mar 19;6(2):289-300. doi: 10.3233/JPD-150741. J Parkinsons Dis. 2016. PMID: 27003780 Free PMC article.
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.Sleep Med. 2013 Aug;14(8):795-806. doi: 10.1016/j.sleep.2013.02.016. Epub 2013 Jul 22. Sleep Med. 2013. PMID: 23886593
Clinical implication of REM sleep behavior disorder in Parkinson's disease.J Parkinsons Dis. 2014;4(2):237-44. doi: 10.3233/JPD-130293. J Parkinsons Dis. 2014. PMID: 24613864 Review.
Cited by 1 article
Comprehensive assessment of PINK1 variants in Parkinson's disease.Neurobiol Aging. 2020 Jul;91:168.e1-168.e5. doi: 10.1016/j.neurobiolaging.2020.03.003. Epub 2020 Mar 10. Neurobiol Aging. 2020. PMID: 32249012
- de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5, 525–535. - PubMed
- Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord 28, 311–318. - PubMed
- Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3, 17013. - PubMed
- Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S, Zecchinelli AL, Canesi M, Mariani CB, Meucci N, Sacilotto G, Zini M, Barichella M, Magnani C, Duga S, Asselta R, Solda G, Seresini A, Seia M, Pezzoli G, Goldwurm S (2016) Survival and dementia in GBA-associated Parkinson’s disease: The mutation matters. Ann Neurol 80, 662–673. - PubMed
- Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, Orr-Urtreger A (2010) LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics 11, 121–125. - PubMed